Rezolute Gets Outperform Upgrade with $11 Target on Positive Phase 3 Tumor Data
RZLT•Rezolute was upgraded to Outperform from Market Perform with an $11 price target. Interim Phase 3 results for ersodetug in tumor hyperinsulinism bolster confidence in a distinct approval pathway separate from the congenital hyperinsulinism indication.
1. Rating Upgrade
Citizens upgraded Rezolute from Market Perform to Outperform, assigning an $11 price target based on positive interim Phase 3 data for ersodetug and anticipated regulatory milestones.
2. Interim Phase 3 Findings
Preliminary Phase 3 results for ersodetug in tumor hyperinsulinism bolstered confidence that its approval pathway can be distinct from the congenital hyperinsulinism indication, potentially streamlining regulatory review.
